Suppr超能文献

回顾性队列研究中阿片类药物使用障碍患者中丁丙诺啡和纳曲酮处方填写的潜在障碍。

Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.

机构信息

Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA; OptumLabs Visiting Scholar, OptumLabs, Eden Prairie, MN, USA.

Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA, USA.

出版信息

J Subst Abuse Treat. 2022 Feb;133:108540. doi: 10.1016/j.jsat.2021.108540. Epub 2021 Jun 17.

Abstract

INTRODUCTION

Medications for opioid use disorder (MOUD) are highly effective, but barriers along the cascade of care for opioid use disorder (OUD) from diagnosis to treatment limit their reach. For individuals desiring MOUD, the final step in the cascade is filling a written prescription, and fill rates have not been described.

METHODS

We used data from a large de-identified database linking individuals' electronic medical records (EMR) and administrative claims data and employed a previously developed algorithm to identify individuals with a new diagnosis of OUD. We included individuals with a prescription for buprenorphine or naltrexone recorded in the EMR. The outcome was a prescription fill within 30 days as reported in claims data. We compared demographic and clinical characteristics between those who did and did not fill the prescription and used a Kaplan-Meier curve to assess whether fill rates differed based on patient copay.

RESULTS

We identified 264 individuals with a new diagnosis of OUD who had a prescription written for buprenorphine or oral naltrexone. Of these, 70% (184) filled the prescription within 30 days, and more than half (57%) filled the prescription on the day it was written. Individuals with prescription copay at or below the mean had a 75% fill rate at 30 days compared with 63% for those with copay above the mean (p < 0.05) and this difference was consistent across fill times (log rank p-value <0.05).

CONCLUSIONS

It is alarming that nearly 1 in 3 MOUD prescriptions go unfilled. More research is needed to understand and reduce barriers to this final step of the OUD cascade of care.

摘要

简介

阿片类药物使用障碍(MOUD)的药物治疗非常有效,但阿片类药物使用障碍(OUD)从诊断到治疗的护理级联过程中的各种障碍限制了其应用。对于渴望接受 MOUD 的患者,该级联的最后一步是开具书面处方,而目前尚未描述其开具率。

方法

我们使用了一个大型匿名数据库中的数据,该数据库将个人的电子病历(EMR)和管理索赔数据联系起来,并使用了先前开发的算法来识别新诊断为 OUD 的个体。我们纳入了在 EMR 中记录有丁丙诺啡或纳曲酮处方的个体。结果是在索赔数据中报告的 30 天内开具处方。我们比较了开具和未开具处方的个体的人口统计学和临床特征,并使用 Kaplan-Meier 曲线评估了患者共付额是否会影响处方开具率。

结果

我们确定了 264 名新诊断为 OUD 的患者,他们的处方开了丁丙诺啡或口服纳曲酮。其中,70%(184 人)在 30 天内开具了处方,超过一半(57%)在开具处方的当天就开具了处方。共付额等于或低于平均值的个体在 30 天时的开具率为 75%,而共付额高于平均值的个体为 63%(p<0.05),并且这种差异在各个开具时间都一致(对数秩检验 p 值<0.05)。

结论

近 1/3 的 MOUD 处方未被开具,令人震惊。需要进一步研究以了解和减少 OUD 护理级联过程中这最后一步的障碍。

相似文献

5
Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
J Subst Abuse Treat. 2022 Jan;132:108645. doi: 10.1016/j.jsat.2021.108645. Epub 2021 Oct 26.
6
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
JAMA Netw Open. 2021 Feb 1;4(2):e210061. doi: 10.1001/jamanetworkopen.2021.0061.
8
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
J Subst Abuse Treat. 2022 Oct;141:108838. doi: 10.1016/j.jsat.2022.108838. Epub 2022 Jul 12.
9
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
J Subst Abuse Treat. 2022 May;136:108686. doi: 10.1016/j.jsat.2021.108686. Epub 2021 Dec 15.
10

引用本文的文献

1
Clinician Prescribing Practices Involving Medications for Alcohol Use Disorder.
Am J Prev Med. 2025 Mar;68(3):446-454. doi: 10.1016/j.amepre.2024.11.006. Epub 2024 Nov 28.
2
Medications for Alcohol Use Disorder: Rates and Predictors of Prescription Order and Fill in Outpatient Settings.
J Gen Intern Med. 2024 Nov;39(14):2708-2715. doi: 10.1007/s11606-024-09002-3. Epub 2024 Aug 26.
4
US payment policy for medications to treat opioid use disorder: landscape and opportunities.
Health Aff Sch. 2024 Feb 27;2(3):qxae024. doi: 10.1093/haschl/qxae024. eCollection 2024 Mar.
5
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
9
Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.
J Subst Use Addict Treat. 2023 Apr;147:208973. doi: 10.1016/j.josat.2023.208973. Epub 2023 Feb 10.
10
Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Int J Drug Policy. 2022 Dec;110:103786. doi: 10.1016/j.drugpo.2022.103786. Epub 2022 Aug 4.

本文引用的文献

1
Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
J Subst Abuse Treat. 2021 Apr;123:108256. doi: 10.1016/j.jsat.2020.108256. Epub 2020 Dec 18.
2
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Addiction. 2021 Jun;116(6):1505-1511. doi: 10.1111/add.15314. Epub 2020 Nov 22.
3
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.
5
Development of a Cascade of Care for responding to the opioid epidemic.
Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi: 10.1080/00952990.2018.1546862. Epub 2019 Jan 24.
7
HIV care providers emphasize the importance of the Ryan White Program for access to and quality of care.
Health Aff (Millwood). 2014 Mar;33(3):394-400. doi: 10.1377/hlthaff.2013.1297.
8
Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review.
Ann Intern Med. 2012 Dec 4;157(11):785-95. doi: 10.7326/0003-4819-157-11-201212040-00538.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验